Therapeutic efficacy of Tirzepatide

Tirzepatide (Mounjaro) is the first and only GIP/GLP‑1 receptor agonist approved by the U.S. Food and Drug Administration (FDA). As a single-molecule medication, it activates the receptors of GIP and GLP‑1, two natural incretin hormones in the human body.

In the SURPASS program, subjects treated with 5 mg tirzepatide achieved a mean reduction in glycated hemoglobin (HbA1c) of 1.8% to 2.1%. For those receiving 10 mg and 15 mg tirzepatide, the mean HbA1c reduction ranged from 1.7% to 2.4% in both dose groups. Although weight management is not an approved indication for this medication, mean body weight change was a key secondary endpoint across all SURPASS studies. Subjects treated with tirzepatide achieved a mean weight reduction ranging from 5.4 kg (5 mg dose group) to 11.3 kg (15 mg dose group).